BioMarin Looks To Offload Roctavian As Gene Therapy’s Sales Drop

 
• By Alaric DeArment
  
BioMarin said it would divest Roctavian, its gene therapy for hemophilia A. (Shutterstock)

More from Gene Therapies

More from Advanced Therapies